Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice
Cells · 21.06.2024 · 13 (13) · 1074
DOI: 10.3390/cells13131074 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 21.06.2024. Verfasst von Marc-Michael Zaruba und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology and Angiology, Medical University Innsbruck, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: Myocardial Infarction, Ventricular Remodeling, Glycine, Mice, Inbred C57BL. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Landes Tirols, Tiroler Wissenschaftsförderung.
Abstract (Originalsprache)
Activation of the CXCL12/CXCR4/ACKR3 axis is known to aid myocardial repair through ischemia-triggered hypoxia-inducible factor-1α (HIF-1α). To enhance the upregulation of HIF-1α, we administered roxadustat, a novel prolyl hydroxylase inhibitor (PHI) clinically approved by the European Medicines Agency 2021 for the treatment of renal anemia, with the purpose of improving LV function and attenuating ischemic cardiomyopathy.
Methods
We evaluated roxadustat’s impact on HIF-1 stimulation, cardiac remodeling, and function after MI. Therefore, we analyzed nuclear HIF-1 expression, the mRNA and protein expression of key HIF-1 target genes (RT-PCR, Western blot), inflammatory cell infiltration (immunohistochemistry), and apoptosis (TUNEL staining) 7 days after MI. Additionally, we performed echocardiography in male and female C57BL/6 mice 28 days post-MI.
Results
We found a substantial increase in nuclear HIF-1, associated with an upregulation of HIF-1α target genes like CXCL12/CXCR4/ACKR3 at the mRNA and protein levels. Roxadustat increased the proportion of myocardial reparative M2 CD206+ cells, suggesting beneficial alterations in immune cell migration and a trend towards reduced apoptosis. Echocardiography showed that roxadustat treatment significantly preserved ejection fraction and attenuated subsequent ventricular dilatation, thereby reducing adverse remodeling.
Conclusions
Our findings suggest that roxadustat is a promising clinically approved treatment option to preserve myocardial function by attenuating adverse remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine III, Cardiology and Angiology, Medical University Innsbruck, 6020 Innsbruck, Austria.
- Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
- Department of Surgery, Kardinal Schwarzenberg Klinikum GmbH, 5620 Salzburg, Austria.
ORCID-Profile: Marc-Michael Zaruba, Patric Schönherr
Förderung
- Landes Tirols
- Tiroler Wissenschaftsförderung
Zitieren
APA
Zaruba, M. M., Staggl, S., Ghadge, S. K., Maurer, T., Gavranovic-Novakovic, J., Jeyakumar, V., Schönherr, P., Wimmer, A., Pölzl, G., Bauer, A., & Messner, M. (2024). Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice. Cells, 13(13), 1074. https://doi.org/10.3390/cells13131074
Vancouver
Zaruba MM, Staggl S, Ghadge SK, Maurer T, Gavranovic-Novakovic J, Jeyakumar V, et al. Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice. Cells. 2024;13(13):1074. doi:10.3390/cells13131074
BibTeX
@article{Zaruba2024,
author = {Zaruba, Marc-Michael and Staggl, Simon and Ghadge, Santhosh Kumar and Maurer, Thomas and Gavranovic-Novakovic, Jasmina and Jeyakumar, Vivek and Schönherr, Patric and Wimmer, Andreas and Pölzl, Gerhard and Bauer, Axel and Messner, Moritz},
title = {Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice},
journal = {Cells},
year = {2024},
volume = {13},
number = {13},
pages = {1074},
doi = {10.3390/cells13131074}
}
EUVIMED